PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 19, 2026Nicotine & Tobacco Research0 citations

Randomized Controlled Trial of a Group-Based Smoking Cessation Intervention for Adults With Serious Mental Illness

View Full Paper
HWHannah WhitmoreEHErin HubbardBCBruce Cooper

Key Points

  • The study aims to evaluate the effectiveness of the PARQuit smoking cessation program in adults with serious mental illness.
  • 99 participants with serious mental illness were randomized to either a physical activity or sedentary group for 12 weeks.
  • Both groups received pharmacotherapy (nicotine replacement therapy or bupropion SR) and cessation counseling.
  • Outcomes were measured at baseline, 6, and 12 weeks, focusing on smoking cessation and psychiatric symptoms.
  • Weekly cigarette consumption decreased significantly from a mean of 76 to 35 cigarettes (mean change: -3.7, 95% CI: -5.2, -2.4).
  • Smoking abstinence increased significantly (McNemar χ2=5.33, p<.05).
  • Psychiatric symptom scores decreased by 0.29 units per week (95% CI: -0.50, -0.09) in both groups.

Abstract

Abstract Introduction Adults with serious mental illness (SMI) have elevated morbidity and mortality, largely attributable to increased cigarette smoking. Effective smoking cessation interventions remain a critical need for this population. This study tested the Parks and Recreation Quit Smoking Program (PARQuit), a multi-component treatment program for adults with SMI. The aims were to compare the effectiveness of the PARQuit physical activity and PARQuit sedentary groups on smoking cessation, smoking reduction, and psychiatric symptom reduction. Methods Ninety-nine participants with SMI were randomized to a physical activity intervention or a sedentary control group, each receiving pharmacotherapy (nicotine replacement therapy (NRT) or bupropion SR) and cessation counseling for 12 weeks in the United States of America, from 2019 through 2025. The PARQuit physical activity group engaged in game-based group exercise (50 minutes, 3 times/week), whereas the PARQuit sedentary group participated in sedentary group activities. Outcomes included smoking cessation (measured at baseline, 6, and 12 weeks) and psychiatric symptoms assessed via the Brief Psychiatric Rating Scale. Results At baseline, participants smoked a mean of 76 cigarettes per week, declining to 35 cigarettes at 12 weeks. Both groups showed a significant linear decline in cigarette consumption over time (mean change: -3.7 cigarettes/week; 95% CI: -5.2, -2.4), with no significant between-group difference. Smoking abstinence increased significantly (McNemar χ2=5.33, p.05). Psychiatric symptoms decreased continually, with scores dropping by 0.29 units per week (95% CI: -0.50, -0.09) in both groups. Conclusions Although there were no significant differences between study groups, both study groups showed a significant reduction in cigarettes smoked each week and in psychiatric symptoms. Group-based counseling and pharmacotherapy likely contributed to these improvements. Future research should assess longer-term outcomes in sustaining smoking cessation. Clinical Trials Registration Number: NCT03950427.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Whitmore et al. (2026) studied this question.

synapsesocial.com/papers/6a0bfdc7166b51b53d37903chttps://doi.org/10.1093/ntr/ntag110
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Poor General Health of the Severely Mentally Ill: Impact of Schizophrenic Diagnosis2005 · 65 citations
  2. 2General-Medical Conditions in Older Patients With Serious Mental Illness2005 · 82 citations
  3. 3Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders2017 · 60 citations
  4. 4Peer support for smoking cessation: a protocol of systematic review and meta-analysis2021 · 10 citations
  5. 5The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities2007 · 205 citations